The JAK-STAT Pathway and Novel Management of Atopic Dermatitis
Speaker: Brett King, MD
1 CME Credit
Brett King, MD
Brett King is associate professor of dermatology at Yale University School of Medicine, specializing in inflammatory and autoimmune skin diseases. He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, and his work has revealed the broad utility of JAK inhibitors for the treatment of alopecia areata, vitiligo, and atopic dermatitis, as well as other conditions. He has lectured nationally and internationally and published numerous articles on this and other topics. Dr. King received his B.A. at the University of California at Santa Cruz, his Ph.D. from Stanford University and his M.D. from Yale University School of Medicine. He completed medical internship at Massachusetts General Hospital and dermatology residency at Yale University School of Medicine.
What to expect:
- Describe the comorbidities of atopic dermatitis
- Describe the pathogenesis of atopic dermatitis
- Summarize the rationale for use of Janus kinase (JAK) inhibitors for atopic dermatitis
- Summarize treatment considerations for patients with atopic dermatitis